The purpose of this study is to learn more about interstitial lung disease through collection of information and blood samples to be used in future research projects. Basic information and a blood sample will be collected in conjunction with clinical care for this study, approximately every 3 months.

This study will see if the experimental medicine MTX-463 can slow or stop idiopathic pulmonary fibrosis (IPF) from worsening in people at least 40 years of age or older. Participants will receive either MTX-463 or a placebo (which contains no active drug) through an intravenous infusion once every 4 weeks, for a total of 6 infusions. Overall, participants will attend a total of 9 visits over the course of approximately 32 weeks, or roughly 8 months.

The overall objective of this proposal is to identify patients with Rheumatoid Arthritis-Interstitial Lung Disease (RA-ILD) that are at the highest risk for progressive disease at the time of diagnosis. Our central hypothesis is that novel quantitative imaging and specific blood markers will be associated with progressive RA-ILD. Approximately 80 subjects will be enrolled from MUSC and participation with last up to 2 years.

DROP-FPF is a clinical study that will assess whether an investigational medication called nerandomilast can reduce the risk of interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) getting worse over time. By learning more about people with early lung abnormalities, it may inform researchers how to reduce the risk of developing progressive pulmonary fibrosis.

Treating autoimmune pulmonary alveolar proteinosis (aPAP) patients with molgramostim nebulizer solution focuses on improving how the lungs function and defend against infection. In this condition, the lungs struggle to clear a natural substance called surfactant, which can make breathing harder. A protein in the body called granulocyte macophage colony-stimulating factor (GM‑CSF) helps activate immune cells that keep the lungs clean and healthy. These cells play an important role in removing buildup and protecting against germs. Increasing their activity can help the lungs work more efficiently. It also helps reduce lung damage by boosting the number of these helpful cells. In addition, this protein supports the formation of certain blood cells that are important for overall health. Molgramostim is a man-made version of this natural protein. It is delivered directly into the lungs using a nebulizer, allowing it to work where it is needed most. Research studies have shown that this treatment is generally safe, well tolerated, and can improve symptoms in people with autoimmune PAP.